Vor Ort
Merkzettel Warenkorb
Produktbild: Phosphodiesterases as Drug Targets
Band 204 - 10%

Phosphodiesterases as Drug Targets

Aus der Reihe Handbook of Experimental Pharmacology
10% sparen

295,99 € UVP 329,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

02.08.2011

Herausgeber

Sharron H. Francis + weitere

Verlag

Springer Berlin

Seitenzahl

522

Maße (L/B/H)

24,1/16/3,3 cm

Gewicht

1010 g

Auflage

2011

Sprache

Englisch

ISBN

978-3-642-17968-6

Beschreibung

Produktdetails

Einband

Gebundene Ausgabe

Erscheinungsdatum

02.08.2011

Herausgeber

Verlag

Springer Berlin

Seitenzahl

522

Maße (L/B/H)

24,1/16/3,3 cm

Gewicht

1010 g

Auflage

2011

Sprache

Englisch

ISBN

978-3-642-17968-6

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Phosphodiesterases as Drug Targets
  • Phosphodiesterase inhibitors: History of pharmacology; PDE inhibitors: factors that influence potency, selectivity and action; A fission yeast-based platform for phosphodiesterase inhibitor high throughput screening and analyses of phosphodiesterase activity; The pharmacokinetics of PDE inhibitors and the impact of this on their efficacy and the therapeutic window; Structural insight into the substrate specificity of phosphodiesterases;
    The GAF-tandem domain of phosphodiesterase 5 as a potential drug target; Small molecule allosteric modulators of phosphodiesterase 4; PDE 2 holoenzyme-insights about full length PDE and mechanism of activation by cGMP binding; Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases with dual-selective phosphodiesterase inhibitors and novel combination therapies; PDE inhibitors in the treatment of inflammatory diseases; Cyclic nucleotides and phosphodiesterases in monocyte differentiation; PDEs as targets for modulating T cell responses; Role of PDEs in adult-onset pulmonary arterial hypertension; Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension; Phosphodiesterase inhibition in heart failure
    Evaluation of the Therapeutic Utility of Phosphodiesterase 5A Inhibition in the mdx Mouse
    Model of Duchenne Muscular Dystrophy; PDEs as targets for intermittent claudication;
    Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase
    inhibitors; Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases; Potential use of PDE inhibitors in treatment of depression and improvement of cognition; PDEs as targets for the treatment of basal ganglia disorders
    Therapeutic potential of PDE inhibitors in parasitic diseases